Clinical proteomics: translating benchside promise into bedside reality
10.1038/nrd891
Crossref journal-article
Springer Science and Business Media LLC
Nature Reviews Drug Discovery (297)
Bibliography

Petricoin, E. F., Zoon, K. C., Kohn, E. C., Barrett, J. C., & Liotta, L. A. (2002). Clinical proteomics: translating benchside promise into bedside reality. Nature Reviews Drug Discovery, 1(9), 683–695.

Authors 5
  1. Emanuel F. Petricoin (first)
  2. Kathryn C. Zoon (additional)
  3. Elise C. Kohn (additional)
  4. J. Carl Barrett (additional)
  5. Lance A. Liotta (additional)
References 83 Referenced 449
  1. Liotta, L. & Petricoin, E. Molecular profiling of human cancer. Nature Rev. Genet. 1, 48–56 (2000).A description of new genomic and proteomic technologies that are allowing the reclassification of human cancer on the basis of molecular portraits instead of histology alone. (10.1038/35049567) / Nature Rev. Genet. by L Liotta (2000)
  2. Ideker, T. et al. Integrated genomic and proteomic analyses of a systematically perturbed metabolic network. Science 292, 929–934 (2001). (10.1126/science.292.5518.929) / Science by T Ideker (2001)
  3. Schwikowski, B., Uetz, P. & Fields, S. A network of protein–protein interactions in yeast. Nature Biotechnol. 18, 1257–1261 (2000). (10.1038/82360) / Nature Biotechnol. by B Schwikowski (2000)
  4. Legrain, P., Jestin, J. L. & Schachter, V. From the analysis of protein complexes to proteome-wide linkage maps. Curr. Opin. Biotechnol. 4, 402–407 (2000). (10.1016/S0958-1669(00)00117-8) / Curr. Opin. Biotechnol. by P Legrain (2000)
  5. Blume-Jensen, P. & Hunter, T. Oncogenic kinase signaling. Nature 411, 355–365 (2001). (10.1038/35077225) / Nature by P Blume-Jensen (2001)
  6. Pawson, T. Protein modules and signaling networks. Nature 373, 573–580 (1995). (10.1038/373573a0) / Nature by T Pawson (1995)
  7. Liotta, L. A. & Kohn, E. C. The microenvironment of the tumour–host interface. Nature 411, 375–379 (2001). (10.1038/35077241) / Nature by LA Liotta (2001)
  8. Ozols, R. F., Rubin, S. C., Thomas, G. M. & Robboy, S. J. in Principles and Practice of Gynecologic Oncology (eds Hoskins, W. J., Perez, C. A. & Young, R. C.) 981–1058 (Lippincott Williams & Wilkins, Philadelphia, Pennsylvania, 2000). / Principles and Practice of Gynecologic Oncology by RF Ozols (2000)
  9. Menon, U. & Jacobs, I. in Principles and Practice of Gynecologic Oncology (eds Hoskins, W. J., Perez, C. A. &, Young, R. C.) 165–182 (Lippincott Williams & Wilkins, Philadelphia, Pennsylvania, 2000). / Principles and Practice of Gynecologic Oncology by U Menon (2000)
  10. Bast, R. C. et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N. Engl. J. Med. 309, 883–887 (1983). (10.1056/NEJM198310133091503) / N. Engl. J. Med. by RC Bast (1983)
  11. Menon, U. & Jacobs, I. J. Recent developments in ovarian cancer screening. Curr. Opin. Obstet. Gynecol. 12, 39–42 (2000). (10.1097/00001703-200002000-00007) / Curr. Opin. Obstet. Gynecol. by U Menon (2000)
  12. Jacobs, I. J. et al. Screening for ovarian cancer: a pilot randomized controlled trial. Lancet 353, 1207–1210 (1999). (10.1016/S0140-6736(98)10261-1) / Lancet by IJ Jacobs (1999)
  13. Cohen, L. S., Escobar P. F., Scharm, C., Glimco, B. & Fishman, D. A. Three-dimensional power Doppler ultrasound improves the diagnostic accuracy for ovarian cancer prediction. Gynecol. Oncol. 82, 40–48 (2001). (10.1006/gyno.2001.6253) / Gynecol. Oncol. by LS Cohen (2001)
  14. Adam, B. L., Vlahou, A., Semmes, O. J. & Wright, G. L. Jr. Proteomic approaches to biomarker discovery in prostate and bladder cancers. Proteomics 1, 1264–1270 (2001). (10.1002/1615-9861(200110)1:10<1264::AID-PROT1264>3.0.CO;2-R) / Proteomics by BL Adam (2001)
  15. Carter, D. et al. Purification and characterization of the mammaglobin/lipophilin B complex, a promising diagnostic marker for breast cancer. Biochemistry 41, 6714–6722 (2002). (10.1021/bi0159884) / Biochemistry by D Carter (2002)
  16. Rosty, C. et al. Identification of hepatocarcinoma-intestine-pancreas/pancreatitis-associated protein I as a biomarker for pancreatic ductal adenocarcinoma by protein biochip technology. Cancer Res. 62, 1868–1875 (2002). / Cancer Res. by C Rosty (2002)
  17. Xiao, Z. et al. Quantitation of serum prostate-specific membrane antigen by a novel protein biochip immunoassay discriminates benign from malignant prostate disease. Cancer Res. 61, 6029–6033 (2001). / Cancer Res. by Z Xiao (2001)
  18. Kim, J. H. et al. Osteopontin as a potential diagnostic biomarker for ovarian cancer. JAMA 287, 1671–1679 (2002). (10.1001/jama.287.13.1671) / JAMA by JH Kim (2002)
  19. Petricoin, E. F. et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 359, 572–577 (2002).This paper describes the invention of a new process and diagnostic paradigm that is based on serum proteomic pattern analysis instead of a discovery effort based on a 'one-biomarker-at-a-time' approach. (10.1016/S0140-6736(02)07746-2) / Lancet by EF Petricoin (2002)
  20. Ball, G. et al. An integrated approach utilizing artificial neural networks and SELDI mass spectrometry for the classification of human tumours and rapid identification of potential biomarkers. Bioinformatics 18, 395–404 (2002). (10.1093/bioinformatics/18.3.395) / Bioinformatics by G Ball (2002)
  21. Ting, K. L., Lee, R. C., Chang, C. L. & Guarino, A. M. The relationship between the mass spectra of drugs and their biological activity — an application of artificial intelligence to chemistry. Comput. Biol. Med. 4, 301–332 (1975). (10.1016/0010-4825(75)90041-4) / Comput. Biol. Med. by KL Ting (1975)
  22. Nicholson, J. K., Connelly, J., Lindon, J. C. & Holmes, E. Metabonomics: a platform for studying drug toxicity and gene function. Nature Rev. Drug Discov. 1, 153–161 (2002). (10.1038/nrd728) / Nature Rev. Drug Discov. by JK Nicholson (2002)
  23. Alizadeh, A. A. et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403, 503–511 (2000). (10.1038/35000501) / Nature by AA Alizadeh (2000)
  24. Golub, T. R. et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 286, 531–537 (1999). (10.1126/science.286.5439.531) / Science by TR Golub (1999)
  25. Lindahl, D., Palmer, J. & Edenbrandt, L. Myocardial SPET: artificial neural networks describe extent and severity of perfusion defects. Clin. Physiol. 19, 497–503 (1999). (10.1046/j.1365-2281.1999.00203.x) / Clin. Physiol. by D Lindahl (1999)
  26. Lapuerta, P. et al. Neural network assessment of perioperative cardiac risk in vascular surgery patients. Med. Decis. Making 18, 70–75 (1998). (10.1177/0272989X9801800114) / Med. Decis. Making by P Lapuerta (1998)
  27. Holland, J. H. (ed.) Adaptation in Natural and Artificial Systems: an Introductory Analysis with Applications to Biology, Control, and Artificial Intelligence 3rd edn (MIT Press, Cambridge, Massachusetts, 1994). / Adaptation in Natural and Artificial Systems: an Introductory Analysis with Applications to Biology, Control, and Artificial Intelligence by JH Holland (1994)
  28. Kohonen, T. Self-organizing formation of topologically correct feature maps. Biol. Cybernetics 43, 59–69 (1982). (10.1007/BF00337288) / Biol. Cybernetics by T Kohonen (1982)
  29. Kohonen, T. The self-organizing map. Proc. IEEE 78, 1464–1480 (1990). (10.1109/5.58325) / Proc. IEEE by T Kohonen (1990)
  30. Tou, J. T. & Gonzalez, R. (eds) in Pattern Recognition Principles (eds Tou, J. T. & Gonzalez, R.) 75–109 (Addison Weley, Reading, Massachusetts, 1974). / Pattern Recognition Principles by JT Tou (1974)
  31. Stoeckli, M., Chaurand, P., Hallahan, D. E. & Caprioli, R. M. Imaging mass spectrometry: a new technology for the analysis of protein expression in mammalian tissues. Nature Med. 7, 493–496 (2001). (10.1038/86573) / Nature Med. by M Stoeckli (2001)
  32. Emmert-Buck, M. R. et al. Laser capture microdissection. Science 274, 998–1001 (1996). (10.1126/science.274.5289.998) / Science by MR Emmert-Buck (1996)
  33. Emmert-Buck, M. R. et al. An approach to proteomic analysis of human tumors. Mol. Carcinog. 27, 158–165 (2000). (10.1002/(SICI)1098-2744(200003)27:3<158::AID-MC2>3.0.CO;2-2) / Mol. Carcinog. by MR Emmert-Buck (2000)
  34. Craven, R. A., Totty, N., Harnden, P., Selby, P. J. & Banks, R. E. Laser capture microdissection and two-dimensional polyacrylamide gel electrophoresis: evaluation of tissue preparation and sample limitations. Am. J. Pathol. 160, 815–822 (2002). (10.1016/S0002-9440(10)64904-8) / Am. J. Pathol. by RA Craven (2002)
  35. Ornstein, D. K. et al. Proteomic analysis of laser capture microdissected human prostate cancer and in vitro prostate cell lines. Electrophoresis 21, 2235–2242 (2000). (10.1002/1522-2683(20000601)21:11<2235::AID-ELPS2235>3.0.CO;2-A) / Electrophoresis by DK Ornstein (2000)
  36. Wulfkuhle, J. D. et al. New approaches to proteomic analysis of breast cancer. Proteomics 1, 1205–1215 (2001). (10.1002/1615-9861(200110)1:10<1205::AID-PROT1205>3.0.CO;2-X) / Proteomics by JD Wulfkuhle (2001)
  37. Jones, M. B. et al. Proteomic analysis and identification of new biomarkers and therapeutic targets for invasive ovarian cancer. Proteomics 2, 76–84 (2002). (10.1002/1615-9861(200201)2:1<76::AID-PROT76>3.0.CO;2-O) / Proteomics by MB Jones (2002)
  38. Knezevic, V. et al. Proteomic profiling of the cancer microenvironment by antibody arrays. Proteomics 1, 1271–1278 (2001). (10.1002/1615-9861(200110)1:10<1271::AID-PROT1271>3.0.CO;2-6) / Proteomics by V Knezevic (2001)
  39. Ahram, M. et al. Proteomic analysis of human prostate cancer. Mol. Carcinog. 33, 9–15 (2002). (10.1002/mc.10019) / Mol. Carcinog. by M Ahram (2002)
  40. Gorg, A. et al. The current state of two-dimensional electrophoresis with immobilized pH gradients. Electrophoresis 21, 1037–1053 (2000). (10.1002/(SICI)1522-2683(20000401)21:6<1037::AID-ELPS1037>3.0.CO;2-V) / Electrophoresis by A Gorg (2000)
  41. Hanash, S. M. Biomedical applications of two-dimensional electrophoresis using immobilized pH gradients: current status. Electrophoresis 21, 1202–1209 (2000). (10.1002/(SICI)1522-2683(20000401)21:6<1202::AID-ELPS1202>3.0.CO;2-I) / Electrophoresis by SM Hanash (2000)
  42. Herbert, B. R., Sanchez, J.-C. & Bini, L. in Proteome Reseach: New Frontiers in Functional Genomics Ch. 2 (eds Wilkens, M. R., Williams, K. L., Appel, R. D. & Hochstrasser, D. F.) 13–30 (Springer–Verlag, New York, 1997). (10.1007/978-3-662-03493-4_2) / Proteome Reseach: New Frontiers in Functional Genomics by BR Herbert (1997)
  43. Shen, Y. et al. High-throughput proteomics using high-efficiency multiple-capillary liquid chromatography with on-line high-performance ESI FTICR mass spectrometry. Anal. Chem. 73, 3011–3021 (2001).The design and application of an automated multiple-capillary liquid chromatography (LC) system for high-throughput proteome analysis using a high-magnetic-field Fourier transform ion cyclotron resonance (FTICR) mass spectrometer for a combined resolving power of > 6 × 107 components. This set provided the characterization of 1,000 proteins from a single capillary LC–FTICR analysis. (10.1021/ac001393n) / Anal. Chem. by Y Shen (2001)
  44. Li, J., Wang, C., Kelly, J. F., Harrison, D. J. & Thibault, P. Rapid and sensitive separation of trace level protein digests using microfabricated devices coupled to a quadrupole-time-of-flight mass spectrometer. Electrophoresis 21, 198–210 (2000). (10.1002/(SICI)1522-2683(20000101)21:1<198::AID-ELPS198>3.0.CO;2-V) / Electrophoresis by J Li (2000)
  45. Gygi, S. P. et al. Quantitative analysis of complex protein mixtures using isotope coded affinity tags. Nature Biotechnol. 17, 994–999 (1999). (10.1038/13690) / Nature Biotechnol. by SP Gygi (1999)
  46. Washburn, M. P., Wolters, D. & Yates, J. R. Large scale analysis of the yeast proteome by multidimensional protein identification technology. Nature Biotechnol. 19, 242–247 (2001).A method for rapid and large-scale proteome analysis by multidimensional LC coupled with tandem mass spectrometry, termed multidimensional protein identification technology (MudPIT). This approach was applied to yeast proteomic analysis, and a total of 1,484 proteins were detected and identified, including the identification of 131 proteins that are membrane localized — a highly problematic class of proteins due to their intrinsic hydrophobic nature. (10.1038/85686) / Nature Biotechnol. by MP Washburn (2001)
  47. Krutchinsky, A. N., Kalkum, M. & Chait, B. T. Automatic identification of proteins with a MALDI-quadrupole ion trap mass spectrometer. Anal. Chem. 73, 5066–5077 (2001). (10.1021/ac010682o) / Anal. Chem. by AN Krutchinsky (2001)
  48. Washburn, M. P., Ulaszek, R., Deciu, C., Schieltz, D. M. & Yates, J. R. Analysis of quantitative proteomic data generated via multidimensional protein identification technology. Anal. Chem. 74, 1650–1657 (2002). (10.1021/ac015704l) / Anal. Chem. by MP Washburn (2002)
  49. Zhou, H., Ranish, J. A., Watts, J. D. & Aebersold, R. Quantitative proteome analysis by solid-phase isotope tagging and mass spectrometry. Nature Biotechnol. 20, 512–515 (2002).A method for directly tagging complex mixtures of peptides and proteins using a solid-phase capture and release process with the captured peptides analysed by microcapillary LC and tandem mass spectrometry (microLC–MS/MS). (10.1038/nbt0502-512) / Nature Biotechnol. by H Zhou (2002)
  50. Zhou, G. et al. 2D differential in-gel electrophoresis for the identification of human esophageal squamous cell cancer-specific protein markers Mol. Cell. Proteomics 1, 117–123 (2002). (10.1074/mcp.M100015-MCP200) / Mol. Cell. Proteomics by G Zhou (2002)
  51. Sreekumar, A. et al. Profiling of cancer cells using protein microarrays: discovery of novel radiation-regulated proteins. Cancer Res. 61, 7585–7593 (2001).This paper describes an antibody-microarray-based platform consisting of 146 distinct antibodies to monitor alterations of protein levels induced by exposure of colon carcinoma cell lines to ionizing radiation. / Cancer Res. by A Sreekumar (2001)
  52. MacBeath, G. Proteomics comes to the surface. Nature Biotechnol. 19, 828–829 (2001). (10.1038/nbt0901-828) / Nature Biotechnol. by G MacBeath (2001)
  53. Walter, G., Bussow, K., Lueking, A. & Glokler, J. High-throughput protein arrays: prospects for molecular diagnostics. Trends Mol. Med. 8, 250–253 (2002). (10.1016/S1471-4914(02)02352-3) / Trends Mol. Med. by G Walter (2002)
  54. Kuruvilla, F. G., Shamji, A. F., Sternson, S. M., Hergenrother, P. J. & Schreiber, S. L. Dissecting glucose signalling with diversity-oriented synthesis and small-molecule microarrays. Nature 416, 653–657 (2002). (10.1038/416653a) / Nature by FG Kuruvilla (2002)
  55. Paweletz, C. P. et al. Reverse-phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front. Oncogene 20, 1981–1989 (2001).The invention of a new type of protein array in which extremely small amounts of clinical material can be immobilized and used to study signalling pathway activation. (10.1038/sj.onc.1204265) / Oncogene by CP Paweletz (2001)
  56. Torhorst, J. et al. Tissue microarrays for rapid linking of molecular changes to clinical endpoints. Am. J. Pathol. 159, 2249–2256 (2001). (10.1016/S0002-9440(10)63075-1) / Am. J. Pathol. by J Torhorst (2001)
  57. Vile, R. G., Russell, S. J. & Lemoine, N. R. Cancer gene therapy: hard lessons and new courses. Gene Ther. 7, 2–8 (2000). (10.1038/sj.gt.3301084) / Gene Ther. by RG Vile (2000)
  58. Wiebe, L. I. & Knaus, E. E. Enzyme-targeted, nucleoside-based radiopharmaceuticals for scintigraphic monitoring of gene transfer and expression. Curr. Pharm. Des. 7, 1893–1906 (2001). (10.2174/1381612013396817) / Curr. Pharm. Des. by LI Wiebe (2001)
  59. Liotta, L. A., Kohn, E. C. & Petricoin, E. F. Clinical proteomics: personalized molecular medicine. JAMA 286, 2211–2214 (2001). (10.1001/jama.286.18.2211) / JAMA by LA Liotta (2001)
  60. Liotta, L. & Petricoin, E. Molecular profiling of human cancer. Nature Rev. Genet. 1, 48–56 (2000). (10.1038/35049567) / Nature Rev. Genet. by L Liotta (2000)
  61. Karpati, G., Li, H. & Nalbantoglu, J. Molecular therapy for glioblastoma. Curr. Opin. Mol. Ther. 1, 545–552 (1999). / Curr. Opin. Mol. Ther. by G Karpati (1999)
  62. Brown, C. K. & Kirkwood, J. M. Targeted therapy for malignant melanoma. Curr. Oncol. Rep. 3, 344–352 (2001). (10.1007/s11912-001-0088-2) / Curr. Oncol. Rep. by CK Brown (2001)
  63. Frankel, A. E., Sievers, E. L. & Scheinberg, D. A. Cell surface receptor-targeted therapy of acute myeloid leukemia: a review. Cancer Biother. Radiopharm. 15, 459–476 (2000). (10.1089/cbr.2000.15.459) / Cancer Biother. Radiopharm. by AE Frankel (2000)
  64. Cheng, J. D., Rieger, P. T., von Mehren, M., Adams, G. P. & Weiner, L. M. Recent advances in immunotherapy and monoclonal antibody treatment of cancer. Semin. Oncol. Nurs. 16 (Suppl. 1), 2–12 (2000). (10.1053/sonu.2000.19775) / Semin. Oncol. Nurs. by JD Cheng (2000)
  65. Gasparini, G. & Gion, M. Molecular-targeted anticancer therapy: challenges related to study design and choice of proper endpoints. Cancer J. Sci. Am. 6, 117–131 (2000). / Cancer J. Sci. Am. by G Gasparini (2000)
  66. Cimoli, G. et al. Signaling proteins as innovative targets for antineoplastic therapy: our experience with the signaling protein c-myc. Tumori. 87, S20–S23 (2001). (10.1177/030089160108700636) / Tumori. by G Cimoli (2001)
  67. Kolonin, M., Pasqualini, R. & Arap, W. Molecular addresses in blood vessels as targets for therapy. Curr. Opin. Chem. Biol. 5, 308–313 (2001). (10.1016/S1367-5931(00)00207-6) / Curr. Opin. Chem. Biol. by M Kolonin (2001)
  68. Rosenwald, A. et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N. Engl. J. Med. 346, 1937–1947 (2002).This paper describes the use of hierarchical clustering analysis of gene-expression profiles of biopsy samples from 240 diffuse large-B-cell lymphoma patients to build a molecular predictor of survival after chemotherapy. (10.1056/NEJMoa012914) / N. Engl. J. Med. by A Rosenwald (2002)
  69. Ponder, B. A. Cancer genetics. Nature 411, 337–341 (2001). (10.1038/35077207) / Nature by BA Ponder (2001)
  70. Evan, G. I. & Vousden, K. H. Proliferation, cell cycle and apoptosis in cancer. Nature 411, 342–348 (2001). (10.1038/35077213) / Nature by GI Evan (2001)
  71. Kaptain, S., Tan, L. K. & Chen, B. HER2/NEU and breast cancer. Diagn. Mol. Pathol. 10, 139–152 (2001). (10.1097/00019606-200109000-00001) / Diagn. Mol. Pathol. by S Kaptain (2001)
  72. Leyland-Jones, B. Trastuzumab: hopes and realities. Lancet Oncol. 3, 137–144 (2002). (10.1016/S1470-2045(02)00676-9) / Lancet Oncol. by B Leyland-Jones (2002)
  73. Sebolt-Leopold, J. S. Development of anticancer drugs targeting the MAP kinase pathway. Oncogene 19, 6594–6599 (2000). (10.1038/sj.onc.1204083) / Oncogene by JS Sebolt-Leopold (2000)
  74. Santen, R. J. et al. The role of mitogen-activated protein (MAP) kinase in breast cancer. J. Steroid Biochem. Mol. Biol. 80, 239–256 (2002). (10.1016/S0960-0760(01)00189-3) / J. Steroid Biochem. Mol. Biol. by RJ Santen (2002)
  75. Thiesing, J. T., Ohno-Jones, S., Kolibaba, K. S. & Druker, B. J. Efficacy of STI571, an ABL tyrosine kinase inhibitor, in conjunction with other antileukemic agents against BCR–ABL-positive cells. Blood 96, 3195–3199 (2000).These experiments show that combinations of Gleevec with interferon-α, hydroxyurea, daunorubicin and cytosine arabinoside have increased antiproliferative effects compared with STI571 alone, suggesting that clinical trials to test these combinations might be worthwhile. (10.1182/blood.V96.9.3195) / Blood by JT Thiesing (2000)
  76. Druker, B. J. et al. Efficacy and safety of a specific inhibitor of the BCR–ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. 344, 1031–1037 (2001). (10.1056/NEJM200104053441401) / N. Engl. J. Med. by BJ Druker (2001)
  77. Vlahos, C. J. & Stancato, L. F. in Platelets and Megakaryoctyes: Methods and Protocols (eds Gibbons, J. M. & Mahaut-Smith, M. P.) (Humana, Totowa, New Jersey, 2002). / Platelets and Megakaryoctyes: Methods and Protocols by CJ Vlahos (2002)
  78. Traxler, P. et al. Tyrosine kinase inhibitors: from rational design to clinical trials. Med. Res. Rev. 21, 499–512 (2001). (10.1002/med.1022) / Med. Res. Rev. by P Traxler (2001)
  79. Zwick, E., Bange, J. & Ullrich, A. Receptor tyrosine kinases as targets for anticancer drugs. Trends Mol. Med. 8, 17–23 (2002). (10.1016/S1471-4914(01)02217-1) / Trends Mol. Med. by E Zwick (2002)
  80. Normanno, N. et al. Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth. Ann. Oncol. 13, 65–72 (2002). (10.1093/annonc/mdf020) / Ann. Oncol. by N Normanno (2002)
  81. Moasser, M. M., Basso, A., Averbuch, S. D. & Rosen, N. The tyrosine kinase inhibitor ZD1839 ('Iressa') inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells. Cancer Res. 61, 7184–7188 (2001).An analysis of the ability of ZD1839 (Iressa) to inhibit the phosphorylation of EGFR, HER2, HER3 and AKT and growth inhibition in a series of human breast cancer cell lines. These studies indicate that HER2-overexpressing tumours might be especially susceptible to Iressa. / Cancer Res. by MM Moasser (2001)
  82. Cuello, M. et al. Down-regulation of the ERBB-2 receptor by trastuzumab (Herceptin) enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in breast and ovarian cancer cell lines that overexpress ERBB-2. Cancer Res. 61, 4892–4900 (2001). / Cancer Res. by M Cuello (2001)
  83. Paweletz, C. P. et al. Rapid protein display profiling of cancer progression directly from human tissue using a protein biochip. Drug Dev. Res. 49, 34–42 (2000). (10.1002/(SICI)1098-2299(200001)49:1<34::AID-DDR6>3.0.CO;2-W) / Drug Dev. Res. by CP Paweletz (2000)
Dates
Type When
Created 22 years, 11 months ago (Sept. 24, 2002, 12:05 p.m.)
Deposited 2 years, 3 months ago (May 18, 2023, 11:29 p.m.)
Indexed 1 week, 1 day ago (Aug. 23, 2025, 12:59 a.m.)
Issued 22 years, 11 months ago (Sept. 1, 2002)
Published 22 years, 11 months ago (Sept. 1, 2002)
Published Print 22 years, 11 months ago (Sept. 1, 2002)
Funders 0

None

@article{Petricoin_2002, title={Clinical proteomics: translating benchside promise into bedside reality}, volume={1}, ISSN={1474-1784}, url={http://dx.doi.org/10.1038/nrd891}, DOI={10.1038/nrd891}, number={9}, journal={Nature Reviews Drug Discovery}, publisher={Springer Science and Business Media LLC}, author={Petricoin, Emanuel F. and Zoon, Kathryn C. and Kohn, Elise C. and Barrett, J. Carl and Liotta, Lance A.}, year={2002}, month=sep, pages={683–695} }